| MeSH term | MeSH ID | Detail |
|---|---|---|
| Wound Infection | D014946 | 12 associated lipids |
| Bacteriuria | D001437 | 7 associated lipids |
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Periodontal Pocket | D010514 | 9 associated lipids |
| Ischemia | D007511 | 18 associated lipids |
| Neuromuscular Diseases | D009468 | 10 associated lipids |
| Peptic Ulcer | D010437 | 19 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Periodontitis | D010518 | 22 associated lipids |
| Nasal Polyps | D009298 | 26 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
| Dermatomycoses | D003881 | 17 associated lipids |
| Fever | D005334 | 35 associated lipids |
| Otitis Media with Effusion | D010034 | 9 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Bronchitis | D001991 | 6 associated lipids |
| Shock, Septic | D012772 | 11 associated lipids |
| Iritis | D007500 | 2 associated lipids |
| Syphilis | D013587 | 6 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Graham DY and Gisbert JP | Letter: clarithromycin dose for H. pylori therapy remains unresolved. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238583 |
| Kositchaiwat C et al. | Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616168 |
| Romero-Gómez M et al. | Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616169 |
| Datta S et al. | Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963080 |
| Cardenas VM et al. | Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. | 2006 | Aliment. Pharmacol. Ther. | pmid:16393310 |
| Kamada T et al. | The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12869086 |
| Lamouliatte H et al. | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535872 |
| Miehlke S et al. | Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535873 |
| Neri M et al. | Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535876 |
| Logan RP et al. | Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:8527618 |
| Lai KC et al. | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535877 |
| Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
| Bruley Des Varannes S et al. | There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472320 |
| Okudaira K et al. | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. | 2005 | Aliment. Pharmacol. Ther. | pmid:15710002 |
| Lane JA et al. | Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. | 2011 | Aliment. Pharmacol. Ther. | pmid:21366634 |
| Sasaki A et al. | Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12823156 |
| Sung JJ et al. | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726384 |
| Azuma T et al. | Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. | 2000 | Aliment. Pharmacol. Ther. | pmid:10807427 |
| Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
| Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
| Malfertheiner P et al. | Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860399 |
| Barth J and Hahne W | Review article: rabeprazole-based therapy in Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849125 |
| Qasim A and O'Morain CA | Review article: treatment of Helicobacter pylori infection and factors influencing eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849124 |
| Vakil N et al. | Seven-day therapy for Helicobacter pylori in the United States. | 2004 | Aliment. Pharmacol. Ther. | pmid:15225176 |
| Yousfi MM et al. | One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8853767 |
| Gisbert JP and Calvet X | Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. | 2011 | Aliment. Pharmacol. Ther. | pmid:21745241 |
| Georgopoulos SD et al. | Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876712 |
| Elizalde JI et al. | Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876713 |
| Hawkey CJ et al. | Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. | 2003 | Aliment. Pharmacol. Ther. | pmid:12694089 |
| John Albert M et al. | High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. | 2006 | Aliment. Pharmacol. Ther. | pmid:17059517 |
| Villoria A et al. | Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. | 2008 | Aliment. Pharmacol. Ther. | pmid:18644011 |
| Furuta T et al. | Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17697203 |
| Wong BC et al. | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. | 2000 | Aliment. Pharmacol. Ther. | pmid:11069326 |
| Kim YS et al. | Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. | 2011 | Aliment. Pharmacol. Ther. | pmid:21923713 |
| Leiper K et al. | Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. | 2008 | Aliment. Pharmacol. Ther. | pmid:18315579 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Ford AC et al. | Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. | 2007 | Aliment. Pharmacol. Ther. | pmid:17944741 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Pilotto A and Malfertheiner P | Review article: an approach to Helicobacter pylori infection in the elderly. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929385 |
| Laine L et al. | A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354200 |
| Xiao SD et al. | A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. | 2001 | Aliment. Pharmacol. Ther. | pmid:11136281 |
| Peterson WL et al. | Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791947 |
| Zullo A et al. | Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. | 2007 | Aliment. Pharmacol. Ther. | pmid:17539982 |
| Nista EC et al. | Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569121 |
| Armuzzi A et al. | The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11148433 |
| Harris AW et al. | Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971302 |
| Moshkowitz M et al. | One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971304 |
| Savarino V et al. | The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886045 |
| Wang WH et al. | High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886046 |
| Zamani M et al. | Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074507 |